Dipyridamole for preventing stroke and other vascular events in patients with vascular disease
Key result
Dipyridamole did not reduce the risk of vascular death (RR 0.99; 95% CI 0.87-1.12) but reduced the risk of further vascular events (RR 0.88; 95% CI 0.81-0.95) in patients with arterial vascular disease.
Why the study?
Does dipyridamole reduce vascular death and vascular events in patients with arterial vascular disease?
Population
23,019 participants across 29 randomised trials with arterial vascular disease
Comparison
Dipyridamole with or without other antiplatelet… vs No drug or an antiplatelet drug other than…
Design
Systematic_review, randomised long-term secondary prevention trials with…
Authors
Discussion
Loading...
Member takes
Implication
Dipyridamole confers no vascular mortality benefit but reduces recurrent events; confirms differential impact on death versus nonfatal outcomes in arterial disease.
Study Design
Type
Systematic Review (n=23,019)
Structured PICO
Does dipyridamole reduce vascular death and vascular events in patients with arterial vascular disease?
P
Population
23,019 participants across 29 randomised trials with arterial vascular disease (starting within six months after presentation)
I
Intervention
Dipyridamole with or without other antiplatelet drugs, treated for more than one month
C
Comparator
No drug or an antiplatelet drug other than dipyridamole
O
Outcome
Vascular death and fatal/non-fatal vascular eventshard clinical
Main Result
Effect estimate: RR 0.99 (95% CI 0.87-1.12)
Dipyridamole reduces the risk of further vascular events in patients with prior cerebral ischemia, but does not reduce vascular death compared to control.
Cite This Study
Schryver et al. (2007) conducted a systematic review in Arterial vascular disease (n=23,019). Dipyridamole vs. No drug or an antiplatelet drug other than dipyridamole was evaluated on Vascular death (RR 0.99, 95% CI 0.87-1.12). Dipyridamole did not reduce the risk of vascular death (RR 0.99; 95% CI 0.87-1.12) but reduced the risk of further vascular events (RR 0.88; 95% CI 0.81-0.95) in patients with arterial vascular disease.